Dysregulation of TNF/TNFR superfamily members: A systemic link between intra- and extrathyroidal manifestations in Graves' disease

Scandinavian Journal of Immunology

Volumn 64, Issue 5, 2006, Pages 523-530

  Quadbeck, B ^b   Stucke, M ^b   Eckstein, A K ^b   Heise, D J ^c   Mann, K ^b   Gieseler, R K ^a,c  

^a LETI Pharma GmbH   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c Rodos BioTarget GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD40 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CLINICAL ARTICLE; DENDRITIC CELL; ENDOCRINE OPHTHALMOPATHY; FEMALE; GRAVES DISEASE; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; INFLAMMATORY CELL; LEUKOCYTE ACTIVATION; MACROPHAGE; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN FAMILY; THYROID DISEASE;

ADULT; ANTIGENS, CD40; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DENDRITIC CELLS; FEMALE; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, TUMOR NECROSIS FACTOR; THYROID GLAND; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 33749541965     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2006.01830.x     Document Type: Article

References (44)

1. McLachlan SM, Nagayama Y, Rapoport B. Insight into Graves' hyperthyroidism from animal models. Endocr Rev 2005;26:800-32.
2. Rapaport B, Chazenbalk GD, Jaume JC, McLachlan SM. The thyrotropin receptor: interaction with thyrotropin and autoantibodies. Endocr Rev 1998;19:673-716.
3. Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993;329:1468-75.
4. Perros P, Kendall-Taylor P. Thyroid-associated ophthalmopathy: pathogenesis and clinical management. Baillieres Clin Endocrinol Metab 1995;9:115-35.
5. Bartley GB, Fatourechi V, Kadrmas EF et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996;121:284-90.
6. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
7. Kabel PJ, Voorbij HA, De Haan M, van der Gaag RD, Drexhage HA. Intrathyroidal dendritic cells. J Clin Endocrinol Metab 1988;66:199-207.
8. Mølne J, Jansson S, Ericson LE, Nilsson M. Adherence of RFD-1 positive dendritic cells to the basal surface of thyroid follicular cells in Graves' disease. Autoimmunity 1994;17:59-71.
9. Quadbeck B, Eckstein AK, Tews S et al. Maturation of thyroidal dendritic cells in Graves' disease. Scand J Immunol 2002;55:612-20.
10. Noelle RJ, Erickson LD. Determinations of B cell fate in immunity and autoimmunity. Curr Dir Autoimmun 2005;8:1-24.
11. Kahaly G, Hansen C, Felke B, Dienes HP. Immunohistochemical staining of retrobulbar adipose tissue in Graves' ophthalmopathy. Clin Immunol Immunopathol 1994;73:53-62.
12. Pappa A, Lawson JM, Calder V et al. T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy. Br J Ophthalmol 2000;84:517-22.
13. + dendritic cells; and loss of γδ and αβ T cell receptor expression. Br J Ophthalmol 2004;88:803-8.
14. Peters JH, Ruhl S, Friedrichs D. Veiled accessory cells deduced from monocytes. Immunobiology 1987;176:154-66.
15. Kabel PJ, de Haan-Meulman M, Voorbij HA, Kleingeld M, Knol EF, Drexhage HA. Accessory cells with a morphology and marker pattern of dendritic cells can be obtained from elutriator-purified blood monocyte fractions. An enhancing effect of metrizamide in this differentiation. Immunobiology 1989;179:395-41.
16. Peters JH, Gieseler R, Thiele B, Steinbach F. Dendritic cells: from ontogenetic orphans to myelomonocytic descendants. Immunol Today 1996;17:273-8.
17. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 1990;360:258-61.
18. Heise D, Peters JH, Schedlowski M, Gieseler R. Maturation of monocyte-derived dendritic cells (MoDC) by autocrine TNF-α signaling. Immunobiology 1999;200:561.
19. Nguyen VT, Benveniste EN. Critical role of tumor necrosis factor-α and NF-κB in interferon-γ-induced CD40 expression in microglia/macrophages. J Biol Chem 2002;277:13796-803.
20. Smith CA, Davis T, Anderson D et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990;246:1019-23.
21. Heise D. Alternative Wege der funktionellen Aktivierung humaner dendritischer Immunzellen. PhD Thesis. Georg August University, Göttingen 2000.
22. Hill CM, Lunec J. The TNF-ligand and receptor superfamilies: controllers of immunity and the Trojan horses of autoimmune disease? Mol Aspects Med 1996;17:455-509.
23. Schonbeck U, Mach F, Libby P. CD154 (CD40 ligand). Int J Biochem Cell Biol 2000;32:687-93.
24. Horai R, Nakajima A, Habiro K et al. TNF-α is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J Clin Invest 2004;114:1603-11.
25. Zhang-Hoover J, Sutton A, Stein-Streilein J. CD40/CD40 ligand interactions are critical for elicitation of autoimmune-mediated fibrosis in the lung. J Immunol 2001;166:3556-63.
26. Chadha S, Miller K, Farwell L et al. Haplotype structure of TNFRSF5-TNFSF5 (CD40-CD40L) and association analysis in systemic lupus erythematosus. Eur J Hum Genet 2005;13:669-76.
27. Liu MF, Chao SC, Wang CR, Lei HY. Expression of CD40 and CD40 ligand among cell populations within rheumatoid synovial compartment. Autoimmunity 2001;34:107-13.
28. Dimitriou ID, Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN. CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjogren's syndrome patients indicating their intrinsic activation. Clin Exp Immunol 2002;127:386-92.
29. Zöller M, McElwee KJ, Vitacolonna M, Hoffmann R. The progressive state, in contrast to the stable or regressive state of alopecia areata, is reflected in peripheral blood mononuclear cells. Exp Dermatol 2004;13:435-44.
30. Zhang HJ, Li DM, Gao DL et al. The relationship between intrathyroidal dendritic cells and humoral immune disorder in Graves' disease. Zhonghua Nei Ke Za Zhi 2005;44:122-4.
31. + memory B cells in blood of patients with autoimmune thyroid disease. Eur J Immunol 2002;32:3126-32.
32. Penna G, Vulcano M, Sozzani S, Adorni L. Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells. Hum Immunol 2002;63:1164-71.
33. Pals ST, Taher TE, van der Voort R, Smit L, Keehnen RM. Regulation of adhesion and migration in the germinal center microenvironment. Cell Adhes Commun 1998;6:111-6.
34. + subset and soluble CD14 as biological markers of inflammatory systemic diseases and monitoring immunosuppressive therapy. Clin Chem Lab Med 1999;37:209-13.
35. Rouzaut A. Subira ML, de Miguel C et al. Co-expression of inducible nitric oxide synthase and arginases in different human monocyte subsets. Apoptosis regulated by endogenous NO. Biochem Biophys Acta 1999;1451:319-33.
36. González A, Calleja A, Santiago E, De Miguel C, Lopez-Zabalza MJ, Lopez-Moratalla N. Correlation of activated monocytes or B cells with T lymphocyte subsets in patients with Graves' disease. Int J Mol Med 1998;1:95-103.
37. + monocytes by glucocorticoid therapy. Clin Exp Immunol 1998;112:501-6.
38. Hart RH, Perros P. Glucocorticoids in the medical management of Graves' ophthalmopathy. Minerva Endocrinol 2003;28:223-31.
39. Brauer VF, Scholz GH. Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids. Med Klin (Munich) 2004;99:71-6.
40. Weetman AP. Medical progress: Graves' disease. N Engl J Med 2000;343:1236-48.
41. Pluvinet R, Petriz J, Torras J et al. RNA-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells. Blood 2004;104:3642-6.
42. Lieberman J, Song E, Lee SK, Shankar P. Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol Med 2003;9:397-403.
43. Alisky JM, Davidson BL. Towards therapy using RNA interference. Am J Pharmacogenomics 2004;4:45-51.
44. Gieseler RK, Marquitan G, Hahn MJ et al. Frontlines. DC-SIGN-specific liposomal targeting and selective intracellular compound delivery to human myeloid dendritic cells: implications for HIV disease. Scand J Immunol 2004;59:415-24.